Copyright Reports & Markets. All rights reserved.

Global PD-1 Inhibitor Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 PD-1 Inhibitor Market Overview

    • 1.1 Product Overview and Scope of PD-1 Inhibitor
    • 1.2 Classification of PD-1 Inhibitor by Types
      • 1.2.1 Global PD-1 Inhibitor Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global PD-1 Inhibitor Revenue Market Share by Types in 2018
      • 1.2.3 Pembrolizumab
      • 1.2.4 Nivolumab
      • 1.2.5 Atezolizumab
      • 1.2.6 Durvalumab
      • 1.2.7 Avelumab
      • 1.2.8 Other
    • 1.3 Global PD-1 Inhibitor Market by Application
      • 1.3.1 Global PD-1 Inhibitor Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Melanoma
      • 1.3.3 Non-small Cell Lung Cancer (NSCLC)
      • 1.3.4 Urothelial Carcinoma
      • 1.3.5 Classical Hodgkin Lymphoma
      • 1.3.6 Renal Cell Carcinoma
      • 1.3.7 Other
    • 1.4 Global PD-1 Inhibitor Market by Regions
      • 1.4.1 Global PD-1 Inhibitor Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) PD-1 Inhibitor Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) PD-1 Inhibitor Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) PD-1 Inhibitor Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) PD-1 Inhibitor Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) PD-1 Inhibitor Status and Prospect (2014-2024)
    • 1.5 Global Market Size of PD-1 Inhibitor (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Merck
      • 2.1.1 Business Overview
      • 2.1.2 PD-1 Inhibitor Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Merck PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Novartis
      • 2.2.1 Business Overview
      • 2.2.2 PD-1 Inhibitor Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Novartis PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Onxeo
      • 2.3.1 Business Overview
      • 2.3.2 PD-1 Inhibitor Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Onxeo PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Sumitomo Dainippon Pharma
      • 2.4.1 Business Overview
      • 2.4.2 PD-1 Inhibitor Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Sumitomo Dainippon Pharma PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Taiwan Liposome Company
      • 2.5.1 Business Overview
      • 2.5.2 PD-1 Inhibitor Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Taiwan Liposome Company PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Tiziana Life Sciences
      • 2.6.1 Business Overview
      • 2.6.2 PD-1 Inhibitor Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Tiziana Life Sciences PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Genentech (Roche)
      • 2.7.1 Business Overview
      • 2.7.2 PD-1 Inhibitor Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Genentech (Roche) PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 AstraZeneca
      • 2.8.1 Business Overview
      • 2.8.2 PD-1 Inhibitor Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 AstraZeneca PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Pfizer
      • 2.9.1 Business Overview
      • 2.9.2 PD-1 Inhibitor Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Pfizer PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

    3 Global PD-1 Inhibitor Market Competition, by Players

    • 3.1 Global PD-1 Inhibitor Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 PD-1 Inhibitor Players Market Share
      • 3.2.2 Top 10 PD-1 Inhibitor Players Market Share
    • 3.3 Market Competition Trend

    4 Global PD-1 Inhibitor Market Size by Regions

    • 4.1 Global PD-1 Inhibitor Revenue and Market Share by Regions
    • 4.2 North America PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 4.3 Europe PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 4.5 South America PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa PD-1 Inhibitor Revenue and Growth Rate (2014-2019)

    5 North America PD-1 Inhibitor Revenue by Countries

    • 5.1 North America PD-1 Inhibitor Revenue by Countries (2014-2019)
    • 5.2 USA PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 5.3 Canada PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico PD-1 Inhibitor Revenue and Growth Rate (2014-2019)

    6 Europe PD-1 Inhibitor Revenue by Countries

    • 6.1 Europe PD-1 Inhibitor Revenue by Countries (2014-2019)
    • 6.2 Germany PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 6.3 UK PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 6.4 France PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 6.5 Russia PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 6.6 Italy PD-1 Inhibitor Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific PD-1 Inhibitor Revenue by Countries

    • 7.1 Asia-Pacific PD-1 Inhibitor Revenue by Countries (2014-2019)
    • 7.2 China PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 7.3 Japan PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 7.4 Korea PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 7.5 India PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia PD-1 Inhibitor Revenue and Growth Rate (2014-2019)

    8 South America PD-1 Inhibitor Revenue by Countries

    • 8.1 South America PD-1 Inhibitor Revenue by Countries (2014-2019)
    • 8.2 Brazil PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia PD-1 Inhibitor Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue PD-1 Inhibitor by Countries

    • 9.1 Middle East and Africa PD-1 Inhibitor Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 9.3 UAE PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa PD-1 Inhibitor Revenue and Growth Rate (2014-2019)

    10 Global PD-1 Inhibitor Market Segment by Type

    • 10.1 Global PD-1 Inhibitor Revenue and Market Share by Type (2014-2019)
    • 10.2 Global PD-1 Inhibitor Market Forecast by Type (2019-2024)
    • 10.3 Pembrolizumab Revenue Growth Rate (2014-2024)
    • 10.4 Nivolumab Revenue Growth Rate (2014-2024)
    • 10.5 Atezolizumab Revenue Growth Rate (2014-2024)
    • 10.6 Durvalumab Revenue Growth Rate (2014-2024)
    • 10.7 Avelumab Revenue Growth Rate (2014-2024)
    • 10.8 Other Revenue Growth Rate (2014-2024)

    11 Global PD-1 Inhibitor Market Segment by Application

    • 11.1 Global PD-1 Inhibitor Revenue Market Share by Application (2014-2019)
    • 11.2 PD-1 Inhibitor Market Forecast by Application (2019-2024)
    • 11.3 Melanoma Revenue Growth (2014-2019)
    • 11.4 Non-small Cell Lung Cancer (NSCLC) Revenue Growth (2014-2019)
    • 11.5 Urothelial Carcinoma Revenue Growth (2014-2019)
    • 11.6 Classical Hodgkin Lymphoma Revenue Growth (2014-2019)
    • 11.7 Renal Cell Carcinoma Revenue Growth (2014-2019)
    • 11.8 Other Revenue Growth (2014-2019)

    12 Global PD-1 Inhibitor Market Size Forecast (2019-2024)

    • 12.1 Global PD-1 Inhibitor Market Size Forecast (2019-2024)
    • 12.2 Global PD-1 Inhibitor Market Forecast by Regions (2019-2024)
    • 12.3 North America PD-1 Inhibitor Revenue Market Forecast (2019-2024)
    • 12.4 Europe PD-1 Inhibitor Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific PD-1 Inhibitor Revenue Market Forecast (2019-2024)
    • 12.6 South America PD-1 Inhibitor Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa PD-1 Inhibitor Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Scope of the Report:
      The global PD-1 Inhibitor market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of PD-1 Inhibitor.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the PD-1 Inhibitor market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the PD-1 Inhibitor market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Merck
      Novartis
      Onxeo
      Sumitomo Dainippon Pharma
      Taiwan Liposome Company
      Tiziana Life Sciences
      Genentech (Roche)
      AstraZeneca
      Pfizer

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Pembrolizumab
      Nivolumab
      Atezolizumab
      Durvalumab
      Avelumab
      Other

      Market Segment by Applications, can be divided into
      Melanoma
      Non-small Cell Lung Cancer (NSCLC)
      Urothelial Carcinoma
      Classical Hodgkin Lymphoma
      Renal Cell Carcinoma
      Other

      Buy now